This site is intended for our US customers.

If you wish to visit our International site, please choose your appropriate region using the selector in the top right of this page.

Commencement of EU Blood Grouping Field Trial

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

 

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited(NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials.

“I am very pleased to announce the start of our European field trials for IH I. This is the next important step in our rigourous development process, that included the V&V performance data which we have previously shared. We feel confident in moving forward to commence the fields trials at this time,” said Franz Walt, Quotient’s Interim Chief Executive Officer, who added, “The concordance portion of the study is moving forward and we expect to make the concordance data available in a press release some time during the month of June.”

To read the full media release please click here.